STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics Inc - ARQT STOCK NEWS

Welcome to our dedicated news page for Arcutis Biotherapeutics (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcutis Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcutis Biotherapeutics's position in the market.

News
Arcutis Announces Pricing of $150 Million Public Offering
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announced the pricing of its underwritten public offering of common stock, selling 15,789,474 shares at $9.50 per share. The gross proceeds are expected to be approximately $150.0 million. The offering is expected to close on March 4, 2024, with the intention to fund commercialization, development, and approval of various programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
offering
-
News
Arcutis Announces Proposed Public Offering
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announces a public offering of $150.0 million of common stock and pre-funded warrants. The underwritten offering includes an option for additional shares. Morgan Stanley, TD Cowen, and Guggenheim Securities are the lead bookrunning managers. The offering is subject to market conditions and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
offering
-
News
Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. partners with Sato Pharmaceutical Co., Ltd. for the development and commercialization of topical roflumilast in Japan, receiving a $25 million upfront payment and potential milestone payments totaling $40 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
News
Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) reported Q4 net product revenues of $13.5 million, a 357% increase YoY, driven by ZORYVE® cream. FDA approval for ZORYVE® foam, 0.3%, for seborrheic dermatitis. PDUFA action date for roflumilast cream, 0.15%, in July 2024. Strong financial position supporting new launches and pipeline development. R&D expenses decreased by 39% in 2023. Company optimistic about 2024 potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.7%
Tags
earnings
-
News
Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announces a quarterly investor conference call and webcast on February 27, 2024, to report fourth-quarter and full-year financial results and provide a business update. The company focuses on immuno-dermatology innovations, with FDA-approved products and a robust pipeline for inflammatory dermatological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.69%
Tags
conferences earnings
-
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) granted 33,750 restricted stock units to five new employees under the 2022 Inducement Plan. The units vest over four years, with 25% vesting annually, subject to continuous employment. The grant date was February 1, 2024, in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.18%
Tags
none
News
Arcutis to Present at the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) will participate in the Guggenheim Healthcare Talks – 6th Annual Biotechnology Conference on February 7, 2024, at 10:00 am ET. The company's management will engage in a fireside chat, with the webcast accessible on the company's website. A replay will be available for 180 days after the conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Journal of the American Academy of Dermatology Publishes ZORYVE (roflumilast) Foam, 0.3% Results for Seborrheic Dermatitis from Pivotal Phase 3 Trial
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. announces the approval of ZORYVE foam, a novel steroid-free topical treatment for seborrheic dermatitis, by the FDA. The Journal of American Academy of Dermatology published positive results from the Phase 3 STRATUM trial, showing 80% of individuals achieving treatment success and 51% reaching complete clearance at Week 8. The study demonstrates significant improvements in itch, scaling, and redness, with ZORYVE foam showing a favorable safety and tolerability profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.34%
Tags
clinical trial
-
News
ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the launch of ZORYVE (roflumilast) topical foam, 0.3%, in the United States for the treatment of seborrheic dermatitis in individuals 9 years of age and older. ZORYVE is a steroid-free foam with a new mechanism of action, providing rapid disease clearance and significant reduction in itch. The drug is available in pharmacies with strong reimbursement from major pharmacy benefit managers. Clinical trials showed that more than half of the subjects achieved complete clearance, and 3 in 4 patients achieved treatment success at 8 weeks, with over 40% achieving success as early as two weeks.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.92%
Tags
none
News
ZORYVE® (Roflumilast) Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. announced new data from the STRATUM study, showing that ZORYVE foam was 3.5 times more likely to achieve IGA Success in patients with seborrheic dermatitis who had an inadequate response, contraindication, or intolerance to steroids. The foam also significantly improved quality of life scores, with minimal side effects. The study was presented at the 2024 Winter Clinical Dermatology Conference in Hawaii.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock ARQT logo
Arcutis Biotherapeutics Inc

Nasdaq:ARQT

ARQT Rankings

#2330 Ranked by Market Cap
#5426 Ranked by Stock Gains
N/A Ranked by Dividends

ARQT Stock Data

1.16B
74.79M
2.5%
95.84%
16.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Westlake Village

About ARQT

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.